Abstract
This Practice Point commentary discusses a study by Gerstein et al. that found an independent relationship between HbA1c level and the risk of cardiovascular mortality, death from any cause, or worsening heart failure in patients with chronic heart failure. The magnitude of this risk increased by ∼10–20% per 1% increase in HbA1c level. These findings add to a growing body of evidence that HbA1c levels predict cardiovascular disease mortality and morbidity in individuals with low, medium and high risks of cardiovascular disease. However, further research will be required to establish whether lowering HbA1c levels to <7% reduces the risk of cardiovascular events. Nevertheless, measurement of HbA1c level could identify and target effective therapies to individuals who are at high risk of cardiovascular disease. Improved understanding of the role of glycemic control in the development of cardiovascular disease might indicate new interventions for treatment and prevention.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Selvin E et al. (2004) Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141: 421–431
Khaw KT and Wareham N (2006) Glycated hemoglobin as a marker of cardiovascular risk. Curr Opin Lipidol 17: 637–643
Gerstein HC et al. (2008) The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 168: 1699–1704
Holman RR et al. (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577–1589
Gerstein HC et al. (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545–2559
ADVANCE Collaborative group et al. (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560–2572
Selvin E et al. (2008) Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 168: 2070–2080
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Khaw, KT. Elevated HbA1c level: a risk factor for cardiovascular disease mortality in patients with chronic heart failure?. Nat Rev Endocrinol 5, 130–131 (2009). https://doi.org/10.1038/ncpendmet1069
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet1069
This article is cited by
-
The influence of pharmacist-led adherence support on glycaemic control in people with type 2 diabetes
International Journal of Clinical Pharmacy (2018)